Department of Haematology, Kings College Hospital, London, UK.
Br J Cancer. 2010 Jan 5;102(1):19-22. doi: 10.1038/sj.bjc.6605443. Epub 2009 Nov 17.
To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma.
A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008).
Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients.
Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP.
评估治疗对晚期滤泡性淋巴瘤影响患者生活质量的健康状态的影响。
对一项 III 期临床试验（Marcus 等人，2008 年）的数据进行了疾病无症状和治疗毒性时间（TWiST）调整的质量调整分析。
环磷酰胺、长春新碱和泼尼松联合利妥昔单抗（R-CVP）治疗组在 TWiST 中平均获得 15.17 个月、在 Q-TWiST 中获得 8.33 个月、在疾病复发中获得 11.30 个月的获益，而毒性无增加与环磷酰胺、长春新碱和泼尼松（CVP）治疗组相比。
与 CVP 相比，利妥昔单抗联合 CVP 治疗组在 12 个月内达到了质量调整生存的显著且具有临床意义的改善。
